Recent studies using a 3D human neuroimmune axis model have demonstrated that blocking CXCL10-CXCR3 interactions through anti-CXCR3 neutralizing antibodies markedly reduces the exacerbation of AD pathology caused by infiltrating CD8+ T cells [6]. This evidence concerns the gene CD8A and Alzheimer disease.